BioScrip (NAS: BIOS) reported earnings on May 10. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), BioScrip beat expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue shrank significantly and GAAP earnings per share dropped to a loss.
Margins contracted across the board.
BioScrip logged revenue of $155.6 million. The two analysts polled by S&P Capital IQ hoped for revenue of $143.5 million on the same basis. GAAP reported sales were 19% higher than the prior-year quarter's $130.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.03. The two earnings estimates compiled by S&P Capital IQ anticipated -$0.01 per share. GAAP EPS were -$0.05 for Q1 compared to $0.05 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 34.4%, 480 basis points worse than the prior-year quarter. Operating margin was 2.9%, 210 basis points worse than the prior-year quarter. Net margin was -1.7%, 390 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $151.8 million. On the bottom line, the average EPS estimate is $0.02.
Next year's average estimate for revenue is $611.8 million. The average EPS estimate is $0.13.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 127 members out of 144 rating the stock outperform, and 17 members rating it underperform. Among 27 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 24 give BioScrip a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on BioScrip is buy, with an average price target of $10.00.
If you're interested in health care stocks like BioScrip, you might want to expand your horizons to find maximum returns. Follow the money and meet a prime candidate for major returns in our new report, "Discover the Next Rule-Breaking Multibagger." Click here for instant access to this free report.
Add BioScrip to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.